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Background: Bladder cancer is the seventh most common cancer worldwide and over 90% are transitional cell
carcinoma (TCC). At the first time of diagnosis at least 70% of TCC present as superficial bladder cancer. Because the
clinical outcome of superficial bladder tumors is relatively unpredictable, there is a pressing need to identify
markers that may predict tumor recurrence and progression and new treatment strategies.
Case presentation: We present a unique case of a 67-year old male who underwent total cystectomy after
repeated trans-urethral resections of the bladder for multifocal non-muscle invasive bladder cancer. The first and
the third tumor were diagnosed as high grade non-infiltrating (HGNI), while the second as carcinoma in situ (CIS).
We performed both array comparative genomic hybridization and a targeted chromosomal profile by UroVysion in
order to detect copy number variations (CNVs) that may be involved with tumor recurrence and progression. The
overall data from this study provide new evidence for the monoclonal origin of urothelial tumor multifocality as
several genetic changes were found in different tumors of the same patient. From the analysis of shared CNVs two
gained regions emerged at 3p25.2 and 12q23.2, including PPARG and ASCL1 genes, respectively. The copy number
level of these genes would seem inversely mutually correlated and highly dependent on histological grade,
because the highest level of amplification at 3p25.2 was evidenced in the two HGNI samples, while the highest
level of copy number gain at 12q23.2 was reported in the CIS.
Conclusion: We provide new evidence on the role of PPARG in initiation and maintenance of bladder cancer. For
the first time we also suggest a possible explanation for the elevated expression of PPARG in this type of tumor
through a focal high level amplification at 3p25.2. Furthermore, a new gene, ASCL1, emerged as a potential
candidate to assist PPARG in bladder carcinogenesis.
Keywords: Multifocal non-muscle-invasive bladder cancer, Transitional cell carcinoma, Array-CGH,
DNA copy number variations, PPARG, FISHBackground
Bladder cancer is the seventh most common cancer
worldwide and the fourth most common cancer diag-
nosed in men in the USA and European countries [1].
Over 90% of bladder cancers are transitional cell carcin-
oma (TCC), and at the first time of diagnosis, at least* Correspondence: angela.bentivegna@unimib.it
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reproduction in any medium, provided the or70% of TCC present as superficial tumors confined to
the mucosa (pTa disease) or lamina propria (pT1). In the
remaining cases, tumors present as muscle invasive dis-
ease (≥pT2) with no history of superficial disease. Low-
grade pTa tumors have a high risk of recurrence (70%)
but rarely progress to muscle-invasive tumors, con-
versely high-grade pTa and pT1 tumors show a high risk
of progression [2].
Because the clinical outcome is relatively unpredict-
able and the limitations of current therapeutic options,
there is a pressing need to identify markers that mayl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment strategies.
According to the scoring system established in 2006
by seven European Organisation for Research and Treat-
ment of Cancer trials, the factors predicting the risk of
recurrence and progression for non-muscle-invasive
bladder cancer (NMIBC) are: i) multifocal disease, ii)
concomitant carcinoma in situ (CIS) and iii) tumor size
>3 cm [3]. Two theories have been proposed to explain
the urothelial tumor multifocality: in the oligoclonal one,
the presence of different clones of altered cells give rise
to polyclonal tumors (field effect); instead, in the mono-
clonal theory, the presence of a single altered cell clone
that spreads to multiple sites by intraepithelial or intra-
luminal seeding, gives rise to tumors with shared genetic
changes in the same patient [4].
In the present study we analyzed three tumor samples
from the same patient who presented multiple recurrences
within a short time-span in order to detect copy number
variations (CNVs) that may be involved with tumor recur-
rence/progression and to assess the molecular genetic
relationships among the multiple coexisting tumors. The
overall data provide new evidence for the monoclonal ori-
gin of multifocal disease, as several genetic changes were
found in different tumors of the same patient. In particu-
lar, one CNV includes the gene for PPARG, a member of
the peroxisome proliferator-activated receptor (PPAR)
subfamily of nuclear receptors, which resulted highly
expressed in bladder cancer and could be an attractive
molecular target for the development of novel treatment
strategies for this type of tumor [5].
Case presentation
We report a unique case of a 67-year old Caucasian male
with NMIBC. Three samples were obtained from trans-
urethral resections of the bladder (TURB) within nine
months: 28CR the first; 41CR, the second, after less than
two months; 3CR, the third, after seven months from the
second. The first TURB evidenced many lesions projecting
into the lumen, with partially solid aspects, occupying the
slum, the bladder neck and almost completely the anterior
wall and the cuff. The patient underwent antibiotic treat-
ment for urinary infections (TAVANIC 500). After the
routinely procession for histological diagnosis, the sections
were stained with haematoxylin and eosin and examined
by two pathologists expert in urological pathology. The
sample was diagnosed as non-infiltrating high grade papil-
lary urothelial carcinoma (HGNI) (according to WHO
2004 classification) (see Figure 1).
The second TURB was performed in the bladder neck,
in both lateral wall and in the cuff, the sample was diag-
nosed as in situ carcinoma (CIS). The patients received
intravescical instillation of epirubicin (50mg) and bacil-
lus Calmette-Guérin (BCG), one cycle/week for 6 weeks,according to European Association of Urology (EAU)
clinical guidelines [6].
The last TURB was performed with Hexvix-based
photodynamic diagnosis and showed hyperemic mucosa,
scars of previous endoscopic resections, multicentric re-
currence of the right retrotrigonal wall. A complete re-
section of recurrence, scars and suspected areas was
carried out. The sample was diagnosed as HGNI. Finally,
the patient underwent total cystectomy.Methods
FISH analysis on Formalin-Fixed, Paraffin-Embedded
(FFPE) tissue sections was performed using UroVysion
bladder cancer kit (Vysis, Wiesbaden, Germany) and
PoseidonTM Repeat FreeTM PPARG (3p25) Break probe
(Kreatech Diagnostics, Amsterdam, Netherlands) apply-
ing protocols described elsewhere [7]. At least 100 cells
for each preparation were scored. The statistical signifi-
cance of differences between chromosome 3 polisomy
and 3p25 amplification was evaluated by Student's t test
on separate counts of 100 nuclei. Differences were con-
sidered as statistically significant with P<0.01. All digital
images were captured using a Leitz microscope (Leica
DM 5000B) equipped with a charge coupled device
(CCD) camera and analyzed by means of Chromowin
software (Tesi Imaging, Milano, Italy).
For array-CGH analysis, genomic DNA was extracted
from fresh biopsies using Wizard genomic DNA extrac-
tion kit (Promega, Madison, WI). Sample preparation,
hybridization, and analysis were performed using human
8 x 60KCGH microarrays, feature extraction, and CGH
analytics software (Agilent, Santa Clara, CA) according to
the manufacturer’s instructions. Sex-matched commercial
DNA samples (Promega) were used as reference DNA.
The arrays were scanned at 2-μm resolution using Agilent
microarray scanner and analyzed using feature extraction
v10.10 and DNA analytics v6.5 software. Significant
chromosomal aberrations have been determined using al-
gorithm ADM-2 (threshold=5; Absolute minimum aver-
age log2 ratio=0.25; at least three or more consecutive
probe sets). A low-level copy number gain was defined as
a log2 ratio >0.25 and a copy number loss was defined as
a log2 ratio <−0.25. A high-level gain or amplification was
defined as a log2 ratio >1.5 [8]. The presence of mosaicism
was calculated as described elsewhere [9].
To analyse which ontology classes were over and
under represented among the genes delineated within
gain and loss regions detected by array-CGH, the GOstat
software (available at http://gostat.wehi.edu.au/) was
used based on AmiGO (the Gene Ontology database)
version 1.8. [10,11].
Immunohistochemistry was performed on FFPE tissue
sections using procedure described elsewhere [12]. Slides
Figure 1 Representative images of the three TURBs. A-D: First TURB (28CR), high grade transitional cell carcinoma, non-infiltrating.
A,C,D: Hematoxylin and eosin staining. B: Ki-67 staining; positive nuclei (pink arrows) and metaphases (black arrows); magnification of the images
in the boxes. E: Hematoxylin and eosin staining of the second TURB (41CR), carcinoma in situ. F-G: Hematoxylin and eosin staining of the third
TURB (3CR), high grade transitional cell carcinoma, non-infiltrating.
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clonal PPAR-gamma antibody (E-8) sc-7273 (Santa Cruz
Biotechnology), then stained with an ABC staining system
kit (Santa Cruz Biotechnology). Breast cancer slides were
used as positive controls. Human ASCL1 protein was
detected by means of a monoclonal antibody
(24B72D11.1, diluted 1:150, BD Biosciences, San Jose,
CA). Antigen retrieval procedure was performed using
microwave heating (three 5 minute passages at 750
Watt) in EDTA buffer (pH 8.0). Immunoreactions were
revealed by a dextran-chain (biotin-free) detection sys-
tem (EnVision, DakoCytomation, Glostrup, Denmark),
using 3,3’-diaminobenzidine (DAB, Dako) as a chromo-
gen. A small cell lung carcinoma sample served as posi-
tive control. To assess the presence of neuroendocrine
phenotype, primary antibodies against chromogranin A(CGA) (Clone LK2H10 + PHE5, diluted 1:200, LabVision
Corporation, Fremont CA), synaptophysin (SYN) (Clone
SY38, diluted 1:50, DAKO, Denmark), CD56/Neural cell
adhesion molecules (NCAM) (Clone 123C3.D5, diluted
1:100, Thermo Fischer Scientific, Fremont CA) were per-
formed. Only for CGA and SYN, antigen retrieval proced-
ure was performed using microwave heating in Target
Retrieval Solution Citrate pH 6,0 (DAKO). Immunoreac-
tions were revealed by LSAB+ System-HRP (DakoCyto-
mation, Denmark), using 3,3’-diaminobenzidine (DAB,
Dako) as chromogen. A neuroendocrine tumor NET G1
sample served as positive control.
UroVysion findings
We performed FISH analysis by means of UroVysion
test on FFPE specimens from the three TURBs. Since
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small in size (Figure 1E), the number of analyzable nu-
clei was an half in comparison to the other two samples
(54 vs 100 nuclei). Significant differences among the
three samples were evidenced (P<0.05, Student t test)
for chromosomes 3 and 17, and for 9p21 locus. Con-
versely, for chromosome 7 a significant difference was
observed only between the first and the second biopsy
(Table 1).
Analyzing the signal distribution, i.e. the percentage of
nuclei with a specific number of signals for each probe,
some similarities can be appreciated between the first
and the third sample. For example, we found mostly loss
or disomy considering the 9p21 locus, with a very low
percentage of nuclei presenting more than 2 signals (7%
and 4% respectively, Figure 2); on the contrary, a higher
presence of polysomy (24%) was observed in the second
biopsy. Furthermore, considering chromosome 3 and 17,
the second specimen showed higher percentage of nuclei
with polysomy.Table 1 Statistical analysis of Urovysion data
A 1^ biopsy 2^ biopsy student t test
chr3 mean 5.22 6.22 p=0,011
d.s. 1.78 3.05
chr7 mean 3.18 3.65 p=0,042
d.s. 1.29 1.47
chr17 mean 3.67 4.37 p=0,008
d.s. 1.34 1.88
9p21 mean 1.4 1.89 p=0,0017
d.s. 0.89 0.92
B 1^ biopsy 3^ biopsy student t test
chr3 mean 5.22 4.1 p=0
d.s. 1.78 1.73
chr7 mean 3.18 3.33 p=0,374
d.s. 1.29 1.08
chr17 mean 3.67 3.07 p=0,0007
d.s. 1.34 1.11
9p21 mean 1.4 0.99 p=0,0012
d.s. 0.89 0.86
C 2^ biopsy 3^ biopsy student t test
chr3 mean 6.22 4.1 p=0
d.s. 3.05 1.73
chr7 mean 3.65 3.33 p=0,128
d.s. 1.47 1.08
chr17 mean 4.37 3.07 p=0
d.s. 1.88 1.11
9p21 mean 1.89 0.99 p=0
d.s. 0.92 0.86
A-B-C: paired comparison of Urovysion data using student t test. Statistically
significant differences are in bold (p<0.05).Array-CGH findings
We also performed array-CGH analysis using genomic
DNA extracted from the three tumors. The three biop-
sies shared 6 CNVs (Figure 3A and B): 4 gains (3p25.2-
p25.1, 3q13.11, 3q13.13, 12q23.2), and 2 losses (2q37.3,
9p24.1). The diagram in Figure 3C suggests a possible
evolution of the shared CNVs starting from the CIS. To
identify possible enrichment of functional groups in the
genes included in these regions, a gene ontology annota-
tion analysis was performed using the GOstat software.
Interestingly, a statistically significant result emerged
only for genes included in the two gained regions
3p25.2-p25.1 and 12q23.2, which include PPARG gene
and ASCL1 gene, respectively (Additional file 1: Table
S1). In particular, the most representative GO classes
were for fat cell differentiation regulation. Moreover, be-
tween the first and the third TURB, which also shared the
same histotype, the number of shared CNVs is signifi-
cantly increased (Figure 3D and Additional file 2: Figure
S1): 12 gains (2p22.3, 3p25.2, 3p25.2-p25.1, 3q11.2-q29,
4p16.3-p11, 5p15.33-p11, 8q22.2-q22.3, 12q13.11-q24.33,
16p12.3-p11.2, 16p11.2-p11.1, 19q12-q13.2, 19q13.33) and
7 losses (1p36.21, 2q35-q37.3, 5q11.1-q13.3, 9p24.3-p13.3,
9q32-q33.2, 9q34.2-q34.3, 14q12-q32.33). In this case,
representative GO classes involved mostly apoptosis for
CNVs in loss, while for CNVs in gain were found apop-
tosis, cell growth and lipid metabolic process (Additional
file 1: Table S2). We also found a CNV in loss (9q34.3),
exclusively shared between the second and the third
sample, while another CNV in gain (11p11.2), between
the first and the second tumor.
Then, we focused on the two shared CNVs at 3p25.2-
p25.1 and 12q23.2. The former spans over 900 Kb and
includes six genes: VGLL4, TAMM41, SYN2, TIMP4,
PPARG, ATG7. Array-CGH data indicated a focal ampli-
fication at the PPARG gene locus (log2 ratio >1.5) in at
least two tumors. In particular, the first and the third bi-
opsy revealed a log2 ratio of 4.60 and 2.08, respectively,
while a low-level copy number gain was identified for the
second biopsy (i.e. the CIS), as the log2 ratio was 0.72.
In order to distinguish a polysomy of chromosome 3
from a true amplification, we performed FISH analysis
with both Urovysion test assay and the dual-color split
probe PPARG (Figure 4). We confirmed high level amp-
lification in the first and third sample (P<<0.01 Student t
test), but not in the second (P=0.24). We also verified
whether the amplification had functional consequences
by immunohistochemistry on the first tumor (28CR).
PPARG showed an heterogeneous expression: negative
tumor cells were mixed with cells at different levels of
positivity in the same area (Figure 4A). Furthermore, we
assessed that its expression was inversely associated with
the expression of Ki67 (Figure 1B), as previously
described [13].
Figure 2 Urovysion signals distributions. Urovysion FISH with red (chromosome 3), green (chromosome 7), aqua (chromosome 17) and gold
(locus 9p21) probes. Comparison of signals distributions in the three TURBs, with an example of the most representative cell.
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and includes ASCL1 gene, a member of the basic helix-
loop-helix (BHLH) family of transcription factors, for
which a low-level copy number gain was evidenced in
the CIS (log2 ratio of 0.50). Interestingly, the first and
the third biopsy shared a more extended region of 86
Mb (from 12q13.11 to 12q24.33), but the averaged log2
ratio was 0.48 and 0.23, respectively. We investigated
whether there were consequences at protein level, but
no evidence for ASCL1-positive immunoreaction was
found. In any case, we cannot exclude that the low-level
copy number gain could cause a faint protein expression
at least in the CIS (data not shown). Finally, since
ASCL1 was indicated as a critical factor involved in neu-
roendocrine differentiation (NE) [14], we assessed the
expression of chromogranin A (CGA), synaptophysin
(SYN), CD56/Neural cell adhesion molecules (NCAM),
but without positive results.Discussion
To date there are two theories to explain the develop-
ment of multifocal urothelial carcinoma: one suggests a
monoclonal origin, while the second a oligoclonal origin
[4]. Since the two theories are not mutually exclusive, a
detailed characterization and comparison of genetic-
genomic alterations of different tumors from the
same patient may provide information in this field. Wepresented a unique case of a 67-year old male with
multifocal non-muscle invasive disease: the first and the
third tumor were HGNI, while the second tumor was a
CIS. Significant differences among all the three tumors
were evidenced for 3 of 4 probes of Urovysion (chromo-
somes 3, 17 and 9p21 locus). The most interesting data
emerged from the analysis of shared CNVs among the
three tumors: the gain at 3p25.2 and 12q23.2, and the
loss at 9p24.1. However, statistically significant ontology
classes (P<0.05) were evidenced only for the two gained
regions, including PPARG and ASCL1 genes, respect-
ively. The former is a member of the peroxisome
proliferator-activated receptor (PPAR) subfamily of nu-
clear receptors that form heterodimers with retinoid X
receptors (RXRs) and regulate transcription of various
genes associated with immune surveillance, cell prolif-
eration, fatty acid regulation, and angiogenesis [15].
PPARG is a regulator of cell growth, adipocyte differenti-
ation and immune surveillance [16]. Additionally, this
nuclear receptor has been implicated in the pathology of
numerous diseases including obesity, diabetes, athero-
sclerosis and in multiple tumor types [17-19]. A possible
role for PPARG in bladder cancer has been suggested
since it was expressed at higher levels in tumor speci-
mens than in benign urothelium [20]. Furthermore, evi-
dence suggests that this nuclear receptor may either
inhibit or facilitate carcinogenesis depending on its level
of activation and the specific milieu in which it is acting
Figure 3 Array-CGH. A: Common CNVs in loss (green) and in gain (red) between the first and the third biopsy. B: Second biopsy. C: Evolution of
shared CNVs; each color identifies a specific CNV. D: Additional shared CNVs acquired during tumor evolution; the shared CNVs are indicated by
arrows.
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of novel targeted treatment strategies was recently
emerged [20,21]. For the first time to our knowledge, a
molecular justification for the increased expression of
PPARG was provided by the presence of a focal high
level amplification at 3p25.2, giving also a possible ex-
planation for the monoclonal origin of tumor multifocal-
ity, as this CNV was present in 3/3 of the analyzed
samples. Because of the limited tumoral area of 41CR
sample, we cannot exclude that the lack of high level
amplification could be influenced by the surrounding
normal tissue, that is revealed by the presence of CNVsin mosaic condition. In addition, since PPARG plays a
critical role in the mechanism of action by which bacillus
Calmette-Guérin (BCG) inhibits bladder tumor growth
[22,23], the decreased level of amplification of the third
sample could be explained thanks to the BCG treatment
after the second TURB.
The second gene evidenced by GOstat analysis,
achaete-scute complex homolog 1 (Drosophila) Human
achaete-scute homolog-1 (ASCL1), encodes a member of
the basic helix-loop-helix (BHLH) family of transcription
factors that is expressed in the central and peripheral
nervous system during development, and promote early
Figure 4 PPARgamma staining (A-C), and FISH with PPARgamma probe (B-D). A-B: First TURB (28CR). C-D: normal bladder.
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correlated with small cell lung carcinomas with neuroen-
docrine features [24], while its constitutive expression in
lung epithelial progenitor cells promotes remodeling and
preneoplasia of pulmonary epithelium [25]. ASCL1 was
recently involved in neuroendocrine differentiation also
in prostate cancer [26]. In this report we associated, for
the first time to our knowledge, ASCL1 gene to bladder
cancer. We evidenced a recurrent low-level copy num-
ber gain including the locus of ASCL1 in almost all the
tumor samples we examined, especially in the CIS. Even
though the three tumors didn't evidence an increased
expression of ASCL1, nor neuroendocrine features, we
cannot exclude that this genomic imbalance could cause
a mis-expression of the protein. It will be interesting to
evaluate any possible alterations of ASCL1 mRNA using
more sensitive techniques as RT-PCR or RNA-RNA in
situ hybridization.Conclusions
This is, to our knowledge, the first report that suggests
a possible explanation for the elevated expression of
PPARG in bladder cancer confirming its critical role in
initiation and maintenance of this type of tumor. Fur-
thermore for the first time a new gene, ASCL1,
emerged as a potential candidate to assist PPARG in
bladder carcinogenesis. Finally, this study provides new
evidence for the monoclonal origin of the urothelial
tumor multifocality, as shared genetic changes were
found in the same patient.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Series Editor of this journal.
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Additional file 2: Figure S1. Array-CGH. A: first biopsy. B: third biopsy.
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